These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1340161)

  • 21. A helix 1-extended hairpin ribozyme exhibits altered cleavage behavior in vitro.
    Moosbauer J; Tabler M
    Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):79-87. PubMed ID: 9149843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy: a bold direction for HIV-1 treatment.
    Sarver N; Rossi J
    AIDS Res Hum Retroviruses; 1993 May; 9(5):483-7. PubMed ID: 8391287
    [No Abstract]   [Full Text] [Related]  

  • 23. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.
    Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F
    Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delivery of recombinant HIV-1-directed antisense and ribozyme genes.
    Sczakiel G; Palú G; James W
    Methods Mol Biol; 1997; 63():389-400. PubMed ID: 9113664
    [No Abstract]   [Full Text] [Related]  

  • 25. Design and expression of chimeric U1/ribozyme transgenes.
    Abounader R; Montgomery R; Dietz H; Laterra J
    Methods Mol Biol; 2004; 252():209-19. PubMed ID: 15017051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of a highly efficient anti-HIV pol hammerhead ribozyme.
    Müller-Kuller T; Capalbo G; Klebba C; Engels JW; Klein SA
    Oligonucleotides; 2009 Sep; 19(3):265-72. PubMed ID: 19732019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts.
    Cagnon L; Rossi JJ
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):251-61. PubMed ID: 10984119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical characterization of an anti-tat ribozyme for therapeutic application.
    Wang L; Witherington C; King A; Gerlach WL; Carr A; Penny R; Cooper D; Symonds G; Sun LQ
    Hum Gene Ther; 1998 Jun; 9(9):1283-91. PubMed ID: 9650613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR.
    Chuah MK; VandenDriessche T; Chang HK; Ensoli B; Morgan RA
    Hum Gene Ther; 1994 Dec; 5(12):1467-75. PubMed ID: 7711139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of HIV-1 replication by an improved hairpin ribozyme that includes an RNA decoy.
    Barroso-DelJesus A; Puerta-Fernández E; Tapia N; Romero-López C; Sánchez-Luque FJ; Martínez MA; Berzal-Herranz A
    RNA Biol; 2005 Apr; 2(2):75-9. PubMed ID: 17132944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.
    Ojwang JO; Hampel A; Looney DJ; Wong-Staal F; Rappaport J
    Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10802-6. PubMed ID: 1438280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of RNA structure on the annealing of a potent antisense RNA directed against the human immunodeficiency virus type 1.
    Eckardt S; Romby P; Sczakiel G
    Biochemistry; 1997 Oct; 36(42):12711-21. PubMed ID: 9335527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation of HIV TAR RNA with RNA scissors.
    Wyszko E; Fuerste JP; Barciszewska M; Szymanski M; Adamiak R; Erdmann VA; Barciszewski J
    J Biochem; 1999 Aug; 126(2):326-32. PubMed ID: 10423525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designing and characterizing hammerhead ribozymes for use in AAV vector-mediated retinal gene therapies.
    Fritz JJ; White DA; Lewin AS; Hauswirth WW
    Methods Enzymol; 2002; 346():358-77. PubMed ID: 11883079
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of antisense ribozyme to alpha (1,3)galactosyl transferase gene on the expression of Gal alpha (1,3)Gal epitope.
    Hayashi S; Nagasaka T; Koike C; Kobayashi T; Hamada H; Yokoyama I; Saito I; Takagi H
    Transplant Proc; 1997; 29(1-2):893. PubMed ID: 9123574
    [No Abstract]   [Full Text] [Related]  

  • 37. Progress toward the structure and therapeutic use of the hairpin ribozyme.
    Earnshaw DJ; Gait MJ
    Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):403-11. PubMed ID: 9303192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective ribozyme delivery in plant cells.
    Perriman R; Bruening G; Dennis ES; Peacock WJ
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):6175-9. PubMed ID: 7597097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hairpin ribozyme gene therapy for AIDS.
    Duarte EA; Leavitt MC; Yamada O; Yu M
    Methods Mol Biol; 1997; 74():459-68. PubMed ID: 9204461
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of antisense approaches to study development.
    Erickson RP
    Dev Genet; 1993; 14(4):251-7. PubMed ID: 8222342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.